IgG4相关疾病淋巴结病:高活动度与不良预后表型及eotaxin-3新生物标志物
该研究纳入85例新诊断IgG4相关疾病(IgG4-RD)患者,55%存在淋巴结病,通过蛋白质组学分析31例患者及6例健康对照发现eotaxin-3为淋巴结病相关潜在血清标志物。淋巴结病患者血清IgG4、IgG4:IgG比值、IgG4-RD应答指数及嗜酸性粒细胞增多均显著更高(P均<0.001),且单用糖皮质激素治疗复发率显著更高(P=0.03)。
要点
- IgG4-RD淋巴结病提示高疾病活动度、嗜酸性粒细胞增多及复发倾向。
- eotaxin-3是淋巴结病相关的新型血清生物标志物。
- 淋巴结病患者单用糖皮质激素复发率显著高于无淋巴结病者。
核心结论
- IgG4-RD淋巴结病代表一种与高疾病活动度、嗜酸性粒细胞增多及复发性疾病相关的表型。
- Eotaxin-3是与IgG4-RD淋巴结病相关的新型生物标志物。
研究设计与样本
- 研究纳入2000年1月至2018年6月新诊断的IgG4-RD患者,进行蛋白质组学分析检测1305种血清蛋白浓度。
- 通过比较有淋巴结病、无淋巴结病及健康对照,提取淋巴结病患者过表达的蛋白,并回顾性分析全部IgG4-RD患者特征与预后。
主要发现
- 85例IgG4-RD患者中55%存在淋巴结病。
- 31例IgG4-RD患者与6例健康对照的蛋白质组学分析显示,eotaxin-3是有淋巴结病者相比无淋巴结病者及健康对照的潜在血清生物标志物。
- 淋巴结病患者血清IgG4、IgG4:IgG比值、IgG4-RD应答指数及嗜酸性粒细胞增多均显著更高(P均<0.001),与器官受累程度无关。
- 单用糖皮质激素治疗的淋巴结病患者复发率显著高于无淋巴结病患者(P=0.03)。
关键数值与推荐
- 淋巴结病患者血清IgG4、IgG4:IgG比值、IgG4-RD应答指数及嗜酸性粒细胞增多较无淋巴结病者显著更高(P均<0.001)。
- 单用糖皮质激素治疗的淋巴结病患者复发率显著高于无淋巴结病者(P=0.03)。
临床怎么用
- 对IgG4-RD合并淋巴结病患者应评估为高活动度表型,关注嗜酸性粒细胞增多及复发风险。
- eotaxin-3可作为淋巴结病相关潜在血清生物标志物用于临床识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To clarify relevant proteins and clinical characteristics of a phenotype of IgG4-related disease (IgG4-RD) with lymphadenopathy. METHODS: We enrolled patients newly diagnosed with IgG4-RD in our department between January 2000 and June 2018 and performed proteomic analysis to measure serum concentrations of 1305 proteins. We extracted proteins overexpressed in patients with IgG4-RD with lymphadenopathy by comparing between those with lymphadenopathy, those without lymphadenopathy and healthy controls. We further reviewed all the patients with IgG4-RD in our institution and investigated the characteristics and prognosis of the patients with IgG4-RD with lymphadenopathy. RESULTS: Eighty-five patients with IgG4-RD were enrolled, of which, 55% had lymphadenopathy. Proteomic analysis in 31 patients with IgG4-RD and 6 healthy controls revealed that eotaxin-3 was a potential serum biomarker in the patients with lymphadenopathy versus those without lymphadenopathy and healthy controls. A cohort of 85 patients with IgG4-RD demonstrated that patients with lymphadenopathy showed a significantly higher serum IgG4, IgG4:IgG ratio, IgG4-RD responder index and eosinophilia (P < 0.001 for all), irrelevant of the extent to which organ involvement developed. Patients with lymphadenopathy treated with glucocorticoid alone relapsed with significantly higher rates than those without lymphadenopathy (P = 0.03). CONCLUSION: Lymphadenopathy in IgG4-RD represents a phenotype associated with high disease activities, eosinophilia and relapsing disease. Eotaxin-3 is a novel biomarker related to IgG4-RD with lymphadenopathy.
引用
- Takanashi S, Kikuchi J, Sasaki T, et al. Lymphadenopathy in IgG4-related disease: a phenotype of severe activity and poor prognosis, with eotaxin-3 as a new biomarker. Rheumatology (Oxford). 2021. PMID: 33167029. doi:10.1093/rheumatology/keaa648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。